Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $162.50 short call and a strike $167.50 long call offers a potential 9.41% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $162.50 by expiration. The full premium credit of $0.43 would be kept by the premium seller. The risk of $4.57 would be incurred if the stock rose above the $167.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 33.47 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
AbbVie Inc (ABBV) Q2 2019 Earnings Call Transcript
Fri, 26 Jul 2019 22:23:50 +0000
ABBV earnings call for the period ending June 30, 2019.
AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?
Fri, 26 Jul 2019 21:51:15 +0000
AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
AbbVie spotlights Allergan deal, new drugs as Humira sales wane
Fri, 26 Jul 2019 15:51:06 +0000
Humira, which treats rheumatoid arthritis and psoriasis, is the world's best-selling medicine, but it has come under fire from cheap rivals in Europe and AbbVie is bracing for competition to the drug in the United States in 2023. AbbVie has tried to stave off competition to Humira by aggressively signing deals to delay potential rivals in its largest market, the United States, and launched a new psoriasis medicine, Skyrizi, this year to help retain some market share.
What's in the Cards for Amarin (AMRN) This Earnings Season?
Fri, 26 Jul 2019 15:50:03 +0000
Amarin's (AMRN) cardiovascular drug, Vascepa is expected to drive sales in the second quarter.
AbbVie does not expect to divest new psoriasis drug
Fri, 26 Jul 2019 14:15:46 +0000
Also on Market Tamer…
Follow Us on Facebook